They also provide an overview of treatment options available and a brief indication of what the future holds GLP-1 receptor agonists: Optimising nutritional outcomes in primary care GLP-1 receptor agonists: Optimising nutritional outcomes in primary care Dietitian Sarah MacAvoy explains that while new weight-loss medications show exciting potential, they also put patients at risk of nutritional deficiencies, and dietitian support is essential Kia ora and welcome to New Zealand Doctor Rata Aotearoa Not a subscriber
Subarachnoid Hemorrhage Model The endovascular perforation model has been described in detail in previous manuscripts ( Experimental Design Animals were randomly assigned to the four separate experiments as described (Figure 1A)
Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility
However, significant weight regain following treatment discontinuation, together with limited accessibility, financial constraints, and ongoing discussions about long-term safety, underscore the need for effective, sustainable long-term strategies
Ensure adequate healthy fats (gallbladder protection)
Qsymia can be effective in helping you lose weight, but it is pricey